Genomic DNA at disease-specific loci (gDNA)

Genomic DNA at disease-specific loci refers to the specific sequences within the human genome that are directly targeted by therapeutic interventions to treat or cure diseases (NHGRI, 2023). This target encompasses the primary genetic material responsible for encoding the instructions for cellular function and development. In the context of modern medicine, targeting genomic DNA involves the use of gene-editing technologies like CRISPR-Cas9, which introduce precise breaks to correct mutations or disrupt harmful genes (Yourgenome, 2022). Additionally, traditional chemotherapeutic agents such as alkylating agents and intercalators interact with DNA to inhibit replication and induce apoptosis in rapidly dividing cells (StatPearls, 2023). The therapeutic goal is typically to restore normal gene function, eliminate pathogenic sequences, or halt the progression of genetic and malignant diseases. By modifying the genome directly, these therapies offer the potential for long-lasting or even curative effects compared to traditional protein-targeting drugs.

Other names

gDNAChromosomal DNANuclear DNAGenetic materialTargeted genomic sequences

Therapeutic agents targeting genomic DNA function through several distinct modalities: site-specific gene editing (e.g., CRISPR-Cas9) utilizes guide RNAs to direct endonuclease activity to specific loci for repair or disruption; alkylating agents (e.g., cisplatin) form covalent cross-links between DNA strands to prevent replication; and intercalating agents (e.g., doxorubicin) insert themselves between planar base pairs to inhibit topoisomerase activity and transcription (PubMed, 2021; StatPearls, 2023).